Pharmacological characterization of interactions of RO 25-6981 with the NR2B (ε2) subunit

被引:38
作者
Lynch, DR
Shim, SS
Seifert, KM
Kurapathi, S
Mutel, V
Gallagher, MJ
Guttmann, RP
机构
[1] Univ Penn, Sch Med, Childrens Seashore House, Dept Pediat, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Childrens Seashore House, Dept Pharmacol, Philadelphia, PA 19104 USA
[3] F Hoffmann La Roche & Co Ltd, Pharma Res Basel Cent Nervous Syst Dis, CH-4070 Basel, Switzerland
[4] Univ Penn, Sch Med, Childrens Seashore House, Dept Neurol, Philadelphia, PA 19104 USA
关键词
glutamate; stroke; ifenprodil; polyamine;
D O I
10.1016/S0014-2999(01)00868-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We used ligand binding to ascertain whether the pharmacological actions of RO 25-6981 [(R:(*), S:(*))-alpha-(4-hydroxyphenyl)-beta -methyl-4-(phenylmethyl)-1-piperidinepropanol] match those of other NR2B (epsilon2) subunit specific agents. RO 25-6981 inhibited binding of I-125-MK801 [iodo-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohept-5,10-imine maleate] to receptors made from NR1a/epsilon2 but not NR1a/epsilon1. Increasing the concentration of spermidine did not change the efficacy of RO 25-6981 and minimally changed the IC50 value. Chimeric epsilon1/epsilon2 receptors demonstrated that the structural determinants for high affinity actions of RO 25-6981 were contained completely within the first 464 amino acids, but no receptor retained wildtype features when the size of the epsilon2 component was decreased further. epsilon 1Q336R receptors were more inhibited by ifenprodil and RO 25-9681 than wildtype epsilon1 receptors in ligand binding assays but not in functional assays. Selected mutations of epsilon 2E200 and epsilon 2E201 also decreased the sensitivity of receptors to ifenprodiI and RO 25-6981. These results suggest that RO 25-6981 shares structural determinants with ifenprodil and other modulators in the NR2B subunit. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:185 / 195
页数:11
相关论文
共 42 条
[1]  
Brimecombe JC, 1998, J PHARMACOL EXP THER, V286, P627
[2]   (3R,4S)-3-[4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl]chroman-4,7-diol:: A conformationally restricted analogue of the NR2B subtype-selective NMDA antagonist (1S,2S)-1-(4-hydroxyphenyl)-2(4-hydroxy-4-phenylpiperidino)-1-propanol [J].
Butler, TW ;
Blake, JF ;
Bordner, J ;
Butler, P ;
Chenard, BL ;
Collins, MA ;
DeCosta, D ;
Ducat, MJ ;
Eisenhard, ME ;
Menniti, FS ;
Pagnozzi, MJ ;
Sands, SB ;
Segelstein, BE ;
Volberg, W ;
White, WF ;
Zhao, DY .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (07) :1172-1184
[3]  
CHAZOT PL, 1994, J BIOL CHEM, V269, P24403
[4]   HIGH-EFFICIENCY TRANSFORMATION OF MAMMALIAN-CELLS BY PLASMID DNA [J].
CHEN, C ;
OKAYAMA, H .
MOLECULAR AND CELLULAR BIOLOGY, 1987, 7 (08) :2745-2752
[5]  
CHEN X, 1995, NAT STRUCT BIOL, V2, P2
[6]  
CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171
[7]  
COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143
[8]  
Coughenour LL, 1997, J PHARMACOL EXP THER, V280, P584
[9]   PHARMACOLOGICAL CHARACTERIZATION AND AUTORADIOGRAPHIC DISTRIBUTION OF POLYAMINE-SENSITIVE [H-3] IFENPRODIL BINDING-SITES IN THE RAT-BRAIN [J].
DANA, C ;
BENAVIDES, J ;
SCHOEMAKER, H ;
SCATTON, B .
NEUROSCIENCE LETTERS, 1991, 125 (01) :45-48
[10]  
Fischer G, 1997, J PHARMACOL EXP THER, V283, P1285